Lasers for quantum, biotech and industrial applications
25 Jul 2023 - BluGlass Limited (ASX:BLG) CEO Jim Haden provides an update on the company, discussing customers and market, product improvements, vertical integration and roadmap.
25 Jul 2023 - BluGlass Limited (ASX:BLG) CEO Jim Haden provides an update on the company, discussing customers and market, product improvements, vertical integration and roadmap.
24 Jul 2023 - Magnis Energy Technologies Limited (ASX:MNS) Managing Director (US) Hoshi Daruwalla and Technical Advisory Committee members Dr Michael Osborne and Wade Guindy discuss progress, focusing on the company's lithium-ion battery manufacturing plant, iM3NY.
18 Jul 2023 - Dr Shane Oliver, Chief Economist at AMP, discusses the impact of interest rates and alternatives for fighting inflation.
14 July 2023 - Shaw and Partners Chief Investment Officer Martin Crabb takes a look at the current economic situation and what it means for portfolios and investments going forward.
12 Jul 2023 - Regan Saveall, CEO of leading UK CBD company Dragonfly Biosciences, discusses the company and its plans to list on the ASX in August.
10 Jul 2023 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent news, including excellent sensitivity and specificity results for the company's SubB2M breast cancer test.
06 Jul 2023 - Tamboran Resources Limited (ASX:TBN) Managing Director and CEO Joel Riddle discusses the company's recent capital raise, the drilling timeline, and agreements with APA Group, Clean Energy Fuels Australia, BP and Shell.
06 Jul 2023 - There has been a global underinvestment in heavy mineral sands projects over the past decade. Newly debuting Chilwa Minerals (ASX:CHW) aims to address this shortage.
28 Jun 2023 - Carolyn Rebeiro from Mining.com.au sits down with ABx Group Limited (ASX:ABX) Managing Director and CEO Dr Mark Cooksey and Corporate Connect Senior Equities Analyst Richard Close for an in-depth look at the company and its value proposition.
27 Jun 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company's lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial.